Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriatic arthritis

Case Report: CPPD Presenting as Pseudosepsis

Hassan Fakhoury, BS, Erin Chew, MD, & Narender Annapureddy, MBBS  |  September 6, 2022

Calcium pyrophosphate crystal deposition disease (CPPD) is an arthritis caused by the accumulation of calcium pyrophosphate crystals. Despite a prevalence of 4–7% among the adult population in Europe and the U.S., it has remained a relatively under-recognized disease owing to its many clinical presentations.1 CPPD may cause an acute mono/oligoarthritis, which may mimic gout or…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:calcium pyrophosphate deposition diseaseGoutpseudosepsisseptic arthritis

An Evidence-Based Drug Update & Guidance for Rheumatologists

Samantha C. Shapiro, MD  |  August 14, 2022

ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…

Filed under:Drug UpdatesEducation & TrainingMeeting ReportsOther ACR meetings Tagged with:AAV FocusRheumACR Education ExchangeU.S. Food and Drug Administration (FDA)

COVID-19 Vaccinations in Immune-Compromised Patients

Arthritis & Rheumatology  |  July 27, 2022

A prospective observational study by Syversen et al. found that patients with immune-mediated inflammatory diseases (IMID) had an attenuated serologic response to the standard two-dose vaccine regimen but a third dose was safe and effective.

Filed under:ConditionsResearch Rheum Tagged with:Arthritis & RheumatologyCOVID-19immune-mediated inflammatory diseases (IMIDs)immunocompromisedResearchvaccination

JAK Inhibitors: Are All Promises Fulfilled?

Samantha C. Shapiro, MD  |  July 22, 2022

A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.

Filed under:Drug UpdatesEULAR/OtherMeeting Reports Tagged with:EULARJAK inhibitorsjakinibsjanus kinase inhibitorRheumatoid Arthritis (RA)

Phase 2 Study Shows Promising Results for Deucravacitinib in PsA

Michele B. Kaufman, PharmD, BCGP  |  July 19, 2022

Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.

Filed under:ConditionsDrug UpdatesEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:deucravacitinibEULARPsAPsoriatic Arthritistyrosine kinase 2 (TYK2)

Never Too Late: Late-Breaking Abstracts Create Excitement

Jason Liebowitz, MD, FACR  |  July 15, 2022

EULAR 2022 (VIRTUAL)—The pace of scientific progress in research medicine is incredible and seems to only accelerate with time. Thus, the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR) session on late-breaking abstracts fittingly captured the excitement and timeliness of a number of research projects that have just recently been completed and…

Filed under:ConditionsEULAR/OtherMeeting Reports Tagged with:baricitinibBimekizumabdeucravacitinibEULARjuvenile idiopathic arthritis (JIA)MethotrexateorelabrutinibPolymyalgia RheumaticaPsoriatic Arthritissarilumabsystemic lupus erythematosus (SLE)

Challenges in Reproductive Health in Rheumatic Disease

Keri Losavio & Julie Nusbaum, MD  |  July 11, 2022

In light of new challenges to individuals’ reproductive rights and the known challenges of clinical management of rheumatic disease patients during pregnancy, we review the current state of reproductive rheumatology and the management of patients with rheumatic disease during pregnancy.

Filed under:ConditionsDrug UpdatesMeeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:Access to Reproductive Health Care Task Forcedisease managementLegalMethotrexatepregnancyreproductive healthReproductive Health in Rheumatic Disease Symposium

ACR-FDA Summit Focuses on Study Design, Safety Considerations

Vanessa Caceres  |  June 21, 2022

Safety considerations and data sources are crucial to consider when designing studies for rheumatology treatments, according to presenters at the 2022 ACR-FDA Summit.

Filed under:Meeting Reports Tagged with:ACR-FDA Summitclinical trialsstudy design

Updates from the ACR’s Committee on Rheumatology Training & Workforce Issues

Jason Liebowitz, MD, FACR  |  June 17, 2022

The ACR’s Committee on Rheumatology Training & Workforce Issues helps young rheumatologists to become successful and find meaning in their work. Here is an update on the committee’s most recent accomplishments.

Filed under:Education & TrainingMeeting ReportsOther ACR meetings Tagged with:ACR Education Exchangeeducation and trainingonline educationTrainingWorkforce

Rheumatologists & Oculoplastic Surgeons Form Unique Partnership in Oregon

James T. Rosenbaum, MD,* Shravani Mikkilineni, MD, MBA, Hadi Khazaei, MD, Davin C. Ashraf, MD, & John D. Ng, MD, MS, FACS  |  June 14, 2022

When my daughter was a second-year internal medicine resident at Massachusetts General Hospital, Boston, she called me excitedly one evening. “Dad,” she reported, “I think I saw the optic nerve for the first time today with an ophthalmoscope.” I suppose I should have shared her exuberance, except that when I went to medical school, a…

Filed under:Practice Support Tagged with:interdisciplinaryoculoplastic surgery

  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 63
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences